Immunodeficient mouse models, particularly severe combined immunodeficient (Prkdcscid and Rag1null) mice, are very useful models for immunology, infectious disease, cancer, stem cell biology and other research. As the number, diversity and specialized research applications of these models increase, so does the difficulty of choosing the most appropriate ones for a particular study. The purpose of this article is to help you make those choices.
To choose the most appropriate immunodeficient mouse model for your research, you will have to consider many factors. Some of the major ones are listed below (Tables 1, 2, and 3 summarize how these factors apply to selected JAX® Mice models):
- Background features. Consider important features of the background strain, such as H2 haplotype, behavior and disease susceptibility. For example, the NOD strain is susceptible to diabetes and is deficient in natural killer (NK), macrophage, antigen presenting cell (APC) and complement activity (Table 1).
- Functionality of various endogenous immune system components. Consider the activity of the mutant's endogenous B cells, T cells, NK cells, APCs and complement (Table 1).
- Leakiness. As applied to Prkdcscid mice, leakiness refers to their tendency (on certain backgrounds) to produce some functional B and T cells as they age. It is higher in mice housed under non-specific pathogen free (SPF) conditions, and it is generally high on the C57BL/6J and BALB/cByJ backgrounds, low on the C3H/HeSnJSmn background, and very low on the NOD/LtSzJ background (Table 1).
- Lifespan. Some immunodeficient mice die young because they are susceptible to thymic lymphomas (Table 3). This limits their use for long-term experiments.
- Radiosensitivity. Prkdcscid mice are sensitive to radiation and therefore cannot be as thoroughly irradiated as other immunodeficient models before being engrafted.
- Breeding performance. Female nude mice are poor breeders: they begin to ovulate late, when 2.5 months old, and stop early, when 4 months old.
- Gene features. Consider how the gene of interest functions, and where it is expressed (Table 2).
- Mutant gene effects. Consider how the mutant gene affects immune responses (such as NK cell, macrophage and complement activity) and interacts with the genetic background of a mutant. For example, the beta 2 microglobulin and perforin mutations lower NK cell activity, the interleukin 2 receptor, gamma chain mutation completely eliminates it, and the scid mutation renders NOD mice resistant to diabetes (Tables 2 and 3).
- Availability. Consider whether the mutant you want is readily available in the quantities you need. If it is not, consider requesting a Dedicated Supply contract with JAX® Services.
- Husbandry. Nude, Rag1null and Pkrdcscid mice should be housed in specific pathogen-free (SPF) environments.
- Research type. Consider the kind of research you are conducting (allograft, xenograft, immunology, cancer, etc.) and how your research will relate to previous and future research.
Table 1. Major features of selected backgrounds for JAX® Mice immunodeficient models and the names of selected models on those backgrounds
Background |
Background Features |
Selected Immunodeficient JAX® Mice Models (stock number) |
Availability Levels |
||
---|---|---|---|---|---|
Innate Immunity(NK, B, APC cells; |
Scid-associated leakiness |
H2 haplotype |
|||
BALB Substrains |
Normal |
High |
d |
CByJ.Cg-Foxn1nu/J(000711) |
4 |
CBySmn.CB17-Prkdcscid/J (001803) | 2 | ||||
C57BL/6J |
Normal |
High |
b |
B6;129S7-Rag1tm1Mom/J (002096) |
3 |
B6.129S7-Rag1tm1Mom/J (002216) | 2 | ||||
B6.CB17-Prkdcscid/SzJ (001913) | 2 | ||||
NOD/LtSzJ |
Impaired |
Low |
g7 |
NOD.129S7(B6)-Rag1tm1Mom/J (003729) | RL |
|
|
|
NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz (004848) |
RL |
|
NOD.CB17-Prkdcscid/SzJ (001303) | 1 | ||||
NOD.Cg-Prkdcscid B2mtm1Unc/J (002570) | 3 | ||||
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557) | RL | ||||
NU/J* |
Normal |
na |
q |
NU/J (002019) |
4 |
na = not applicable
*Harbors the Foxn1nu mutation
Table 2. Gene names and functions for models in Table 1.
Gene names | Function |
---|---|
B2m beta-2 microglobulin |
B2m is required for normal expression of major histocompatibility class I proteins (displaying viral and self antigens to potentially responsive T cells) and for CD8+ T cell maturation and NK cell development |
Foxn1 forkhead box N1, formerly Hfh11 |
The Foxn1nu mutation is commonly known as nude. Homozygous mutants lack a thymus and therefore are T cell deficient; they respond very poorly to thymus-dependent antigens, are unable to reject allogeneic and xenogeneic grafts, and have greatly increased susceptibility to infection. |
Il2rg interleukin 2 receptor, gamma chain |
Il2rg is indispensable for IL2, IL4, IL7, IL9, IL15, and IL21 high-affinity binding and signaling; in mice, it is also thought to play a key role in mediating susceptibility to thymic lymphomas. Thus, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice do not develop thymic lymphomas characteristic of aging NOD.CB17-Prkdcscid/SzJ mice. Most importantly, Il2rg deficiency blocks the development of NK cells and causes other defects in innate immunity. |
Prf1 perforin 1 (pore-forming protein) |
Prf1 is a critical component of the lytic pathway by which NK and CD8+ lymphocytes kill targeted cells. |
Prkdc protein kinase, DNA-activated, catalytic polypeptide |
The scid mutation in the Prkdc gene stands for severe combined immunodeficient. Prkdc is instrumental in repairing double-stranded DNA breaks and in recombining the variable (V), diversity (D), and joining (J) segments of immunoglobulin and T-cell receptor genes. Homozygous mutants have no mature T and B cells, cannot mount cell-mediated and humoral adaptive immune responses, do not reject allogeneic and xenogeneic grafts, and are useful cancer research models. The scid mutation renders NOD mice diabetes-free and thereby makes them useful for adoptive transfer of diabetes by T cells. (Note: the NOD.NON-Thy1a/1Lt (004483) strain provides an allotypically marked T cell population and develops diabetes at the same rate and frequency as does the standard NOD/LtJ (Thy1b) strain. Thus, it is useful as a T cell donor source.) |
Rag1 recombination activating gene 1 |
Rag1 is essential for the V(D)J gene rearrangements that generate functional antigen receptors in T and B cells; homozygous Rag1tm1Mom mutants have no mature, functional T and B cells. The Rag1tm1Mom mutation on the NOD background renders NOD mice diabetes-free. Aging NOD.129S7(B6)-Rag1tm1Mom/J mice develop B cell lymphomas at a high frequency. |
Table 3. Major characteristics of featured severely immunodeficient JAX® mouse models.
Model (stock number) | Availability | Lifespan (in months) | Primary References |
---|---|---|---|
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557) |
3 |
>16 |
Ishikawa et al. 2005; |
Advantages: | |||
Our most useful and versatile model
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
NOD.CB17-Prkdcscid/SzJ (001303) |
1 |
8.5 |
Shultz et al. 1995 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz (004848) |
RL |
8.5 |
Shultz et al. 2003; Minamiguchi et al. 2005 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
NOD.Cg-Prkdcscid B2mtm1Unc/J (002570) |
3 |
6.3 |
Christianson et al. 1997 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
NOD.129S7(B6)-Rag1tm1Mom/J (003729) |
RL |
10.5 |
Shultz et al. 2000 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
B6.129S7-Rag1tm1Mom/J (002216) |
2 |
ND |
Mombaerts et al. 1992 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
B6;129S7-Rag1tm1Mom/J (002096) |
3 |
ND |
Mombaerts et al. 1992 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
B6.CB17-Prkdcscid/SzJ (001913) |
2 |
ND |
Christianson et al. 1996 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
CBySmn.CB17-Prkdcscid/J (001803) |
2 |
ND |
Custer et al. 1985 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
NU/J (002019) |
4 |
ND |
Kelland 2004 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
|||
Model (stock number) | Availability | Lifespan | Primary References |
CByJ.Cg-Foxn1nu/J (000711) |
4 |
ND |
Committee 1989 |
Advantages: | |||
|
|||
Disadvantages: | |||
|
References
Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, Schweitzer IB, Rajan TV, Gott B, Roopenian DC, Shultz LD. 1997. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol 158:3578-86.
Christianson SW, Greiner DL, Schweitzer IB, Gott B, Beamer GL, Schweitzer PA, Hesselton RM, Shultz LD. 1996. Role of natural killer cells on engraftment of human lymphoid cells and on metastasis of human T-lymphoblastoid leukemia cells in C57BL/6J-scid mice and in C57BL/6J-scid bg mice. Cell Immunol 171:186-199.
Committee on Immunologically Compromised Rodents 1989. Hereditary immunodeficiencies. Immunodeficient Rodents, a Guide to their Immunobiology, Husbandry, and Use, National Academy Press. 69-71.
Custer RP, Bosma GC, Bosma MJ. 1985. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol 120:464-77.
Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. 2005. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain null mice. Blood 106:1565-73.
Kelland LR. 2004. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827-36.
Minamiguchi H, Wingard JR, Laver JH, Mainali ES. Shultz LD, Ogawa M. 2005. An assay for human hematopoietic stem cells based on transplantation into nonobese diabetic recombination activating gene-null perforin-null mice. Biol Blood Marrow Transplant 11:487-494.
Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-77.
Shultz LD. Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. 2005. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R_null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:6477?89.
Shultz LD, Banuelos S, Lyons B, Samuels R, Burzenski L, Gott B, Lang P, Leif J, Appel M, Rossini A, Greiner DL. 2003. NOD/LtSz-Rag1nullPfpnull mice: a new model system with increased levels of human peripheral leukocyte and hematopoietic stem-cell engraftment. Transplantation 76:1036-42.
Shultz LD, Lang PA, Christianson SW, Gott B, Lyons B, Umeda S, Leiter E, Hesselton R, Wagar EJ, Leif JH, Kollet O, Lapidot T, Greiner DL. 2000. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol 164:2496-507.
Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH. 1995. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154:180-91.